<DOC>
	<DOC>NCT02648451</DOC>
	<brief_summary>- To evaluate tolerance and acceptability of AYMES ROME in patients requiring supplementary oral nutritional support compared with currently available alternatives. - To obtain data to support a submission to Advisory Committee on Borderline Substances (ACBS) for AYMES ROME (to allow for prescription in the community at National Health Service (NHS) expense).</brief_summary>
	<brief_title>Acceptability and Tolerance Study of New Oral Nutritional Supplement</brief_title>
	<detailed_description>To evaluate tolerance and acceptability of AYMES ROME in patients requiring supplementary oral nutritional support compared with currently available alternatives, measuring outcomes of GI effects, Compliance, product preference,convenience etc. To obtain data to support an ACBS submissions for AYMES ROME (to allow for prescription in the community at NHS expense).</detailed_description>
	<mesh_term>Malnutrition</mesh_term>
	<criteria>Adult patients (â‰¥18 years) who are able to communicate their views regarding acceptability. Patients established on an oral nutritional supplement, being prescribed 12 ONS providing approximately 300kcal/day Patients expected to require oral nutritional supplementation for at least 2 further weeks. Informed consent obtained. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study Patients requiring a milk free diet Patients with medical or dietary contraindication to any feed ingredients (see appendix 2 of protocol for full list) Patients with significant renal or hepatic impairment Patients with swallowing impairment requiring thickened fluids Patients with inflammatory bowel disease or previous bowel resection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>